The US Treasury Department recently unveiled draft regulations aimed at restricting outbound investment into specific Chinese sectors, including biotechnology. These proposed rules are designed to oversee and potentially limit the flow of American capital into technologies deemed sensitive to national security.

Industry analysts, such as David Zhang of Trivium China, suggest that these measures will create significant hurdles for Chinese biotech firms attempting to attract direct US investment or establish joint ventures. The primary concern is that the increased regulatory scrutiny will complicate deal structures, making it more difficult for Chinese companies to expand globally or partner with American entities.

While the current draft rules focus on investment and joint ventures, they do not explicitly target drug licensing agreements. However, there is uncertainty regarding how these regulations might evolve or affect the broader landscape of US-China biotech cooperation. The situation reflects a growing trend of geopolitical tension influencing financial and scientific collaboration, as Washington seeks to curb the transfer of technology and capital to Chinese firms in strategic industries.